EGFR and non-small cell lung carcinoma: The issue of infusion-related reactions associated with the intravenous administration of amivantamab certainly may negatively influence physicians when they have to choose among the available options for the treatment of advanced EGFR mutant NSCLC, mainly in the first-line setting.